China Revises Drug Clinical Trial GCP to Align with ICH E6(R3)

On June 8, 2026, the National Medical Products Administration, the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration issued the revised “Good Clinical Practice for Drug Clinical Trials” through “Announcement No. 50 of 2026.”

The revised GCP will take effect on September 1, 2026, replacing the 2020 version issued under “Announcement No. 57 of 2020.” For international pharmaceutical and biotechnology companies conducting or planning drug trials in China, the revision materially strengthens expectations for:

• Sponsor oversight
• Site accountability
• Ethics review
• Data governance
• Risk-based quality management.

Key Takeaways for Overseas Sponsors

• Closer Alignment with ICH E6(R3): The revised GCP adopts key ICH E6(R3) principles, including quality by design, fitness for purpose, and risk proportionality, while maintaining China-specific regulatory requirements. 
• Clearer Accountability Across Clinical Trials: Sponsors remain ultimately responsible for trial activities, including outsourced work, while investigators and trial institutions face strengthened obligations for oversight, participant protection, and data quality. 
• Stronger Data Governance Requirements: A new Data Governance chapter raises expectations for computerized systems, audit trails, electronic signatures, data integrity, and information security. 
• Enhanced Ethics and Participant Protection: Ethics committees assume a larger role in safety oversight, continuing review, informed consent, vulnerable populations, and significant non-compliance. 
• Early Preparation Is Essential: Companies should review SOPs, quality systems, vendor oversight, contracts, safety reporting processes, and inspection readiness before the September 1, 2026 implementation date.

Key Changes

The new GCP contains six chapters and 54 articles. It introduces a dedicated chapter on data governance and removes prior chapters on trial protocols, investigator’s brochures, and essential document management, as these topics are addressed through “ICH E6(R3)” and related technical guidance.

This structure reflects a broader regulatory direction. China expects sponsors and sites to apply internationally recognized GCP principles while maintaining clear accountability under Chinese law.

The revision incorporates three core concepts introduced in “ICH E6(R3): Guideline for Good Clinical Practice”:

• Quality by design 
• Fitness for purpose 
• Risk proportionality 

For overseas sponsors, the revised GCP remains a China-specific compliance framework and should be treated as both a global alignment measure and a local implementation update.

Quality by Design Moves to the Center of Trial Planning

The revised GCP requires sponsors to build quality into trial design and conduct from the outset. Sponsors must identify critical quality factors, assess risks to those factors, and implement proportionate risk-control measures. This shifts the focus away from relying mainly on downstream monitoring to detect issues after they occur.

In practice, quality expectations now need to be reflected across:

• Protocol design
• Vendor selection
• Site activation
• Data systems
• Informed consent
• Safety reporting
• Monitoring
• Statistical analysis

Sponsor Accountability Becomes More Explicit

The sponsor is confirmed as ultimately responsible for clinical trial-related activities, which extends to CROs, subcontractors, laboratories, data systems, investigational medicinal product management, safety reporting, and overall trial quality.

Sponsors may delegate tasks to qualified service providers but remain responsible for supervising and managing those providers and any approved subcontracting activities. Further subcontracting requires the sponsor’s prior written consent.

Clinical trial contracts should clearly define:

• Roles and responsibilities 
• Rights and obligations 
• Subcontracting controls 
• Conflict-of-interest safeguards 
• Oversight expectations 
• Trial funding arrangements 

Risk Management Must Continue Throughout the Trial

Sponsors must identify risks that may affect critical quality factors, assess their likelihood and impact, and define acceptable risk ranges where appropriate.

When predefined thresholds are exceeded, sponsors must assess whether corrective action is required. Significant quality issues, including deviations from acceptable ranges and remedial measures, must be summarized in the clinical trial report.

This will affect sponsor SOPs, monitoring plans, quality management plans, audit programs, and clinical study reports.

Safety Oversight Requires Stronger Local Execution

The revised GCP requires sponsors to continuously assess safety information and act when new risks may affect participant safety, participant willingness, trial conduct, or ethics approval.

Sponsors must rapidly report suspected unexpected serious adverse reactions (SUSARs) and other potential serious safety risk information to the Center for Drug Evaluation of the NMPA. They must also submit development safety update reports and notify investigators and ethics review committees as required.

For international sponsors, this places greater pressure on China-specific safety workflows, local medical review, translation controls, and alignment between global safety databases and China reporting timelines.

Principal Investigators and Trial Sites Face Clearer Duties

The revised GCP clarifies that the principal investigator is ultimately responsible at the clinical trial site.

This includes responsibility for participant rights, participant safety, and trial quality. Clinical trial institutions must also establish and operate a quality management system for drug clinical trials.

Certain duties should not simply be delegated. In principle, clinical trial decisions, key confirmations, and formal reports to ethics committees, institutions, and sponsors should remain with the principal investigator.

Where external parties are entrusted with trial-related responsibilities, prior sponsor consent is required. The principal investigator and clinical trial institution remain ultimately responsible for authorized or entrusted work.

Source Records and SAE Reporting Move Higher on the Compliance Agenda

Except where otherwise specified in the protocol or approved trial documents, principal investigators must immediately report serious adverse events in writing to the sponsor and the ethics review committee, unless the protocol or other approved documents specify otherwise.

Investigators must also review and sign off on sponsor-provided safety information, assess whether participant treatment should be adjusted, and communicate with participants when necessary.

The revised GCP also strengthens expectations for source records. Records must be attributable, legible, contemporaneous, original, accurate, and complete. Any changes must be traceable, preserve the original entry, and record the reason for modification.

For patient trials, relevant medical records must be entered into the outpatient or inpatient medical record system.

Data Governance Becomes a Standalone Compliance Priority

The new Data Governance chapter is a major structural change. It reflects the growing use of electronic systems, digital data flows, remote tools, and outsourced data processes in modern clinical development. Sponsors, principal investigators, and clinical trial institutions must assume data governance responsibilities within their respective scopes.

Data from any source, including data collected through computerized systems, must include corresponding metadata and audit trails. Processes must also exist for reviewing data and metadata, correcting errors, and ensuring traceability of corrections.

This has direct implications for EDC systems, ePRO tools, laboratory data transfers, imaging platforms, randomization tools, safety systems, and electronic signatures.

Computerized Systems Must Be Validated, Secure, and Traceable

All computerized systems used in clinical trials must ensure the reliability, traceability, and security of trial data.

The revised GCP requires:

• SOPs for system setup, installation, and use 
• User training 
• Data backup and contingency measures 
• Issue management workflows 
• User access and permission controls 
• Audit trail functions 
• Validated system performance 
• Compliance with China electronic signature requirements 

Sponsors using global platforms should verify that those systems can meet China-specific expectations for validation, access control, metadata, audit trails, data security, and inspection support.

Ethics Review Committees Gain a Stronger Gatekeeping Role

The revised GCP strengthens the ethics review committee’s role in protecting participant rights, interests, and safety.

Ethics review now carries greater weight in trial initiation, continuing review, protocol deviations, safety information, vulnerable populations, participant compensation, and non-compliance management.

Ongoing trials must undergo periodic follow-up review based on trial risk, with intervals not exceeding 12 months.

Ethics committees must also promptly review serious adverse events, immediate-hazard protocol deviations or amendments, serious and persistent non-compliance, increased-risk changes, and new information that may affect participant safety or trial conduct.

Informed Consent Requirements Become More Detailed

The revised GCP reinforces informed consent as a core participant protection mechanism. Consent forms and participant-facing materials must be sufficient, complete, easy to understand, and approved by the ethics review committee. Participants or legally authorized representatives must have adequate time to understand the trial and ask questions.

The revised GCP also sets detailed requirements for minors, persons without or with limited civil capacity, emergency enrollment, impartial witnesses, and trials with no expected benefit.

International sponsors should review China informed consent templates carefully rather than relying only on global master forms.

Compensation and Indemnification Need Careful Review

Ethics review committees must assess whether participant compensation is reasonable and whether trial materials avoid coercion, inducement, or improper influence.

Sponsors must provide investigational medicinal products free of charge, pay trial-related medical testing costs , and provide appropriate legal and financial insurance or guarantees for compensation or indemnification for clinical trial-related harm.

This will affect trial budgets, insurance arrangements, informed consent wording, and site contract terms.

Priority Actions Before September 2026

With the revised GCP taking effect on September 1, 2026, sponsors should begin evaluating the impact on their China clinical development programs and identifying any operational, quality, or compliance gaps.

Final Thoughts

China’s 2026 revision of the “Good Clinical Practice for Drug Clinical Trials” reflects a broader regulatory shift from document-based compliance toward integrated quality management, accountable oversight, risk-based decision-making, and robust data governance.

The companies best positioned under the revised GCP will be those that can demonstrate not only protocol compliance, but also effective quality management systems, robust sponsor oversight, reliable data governance, and inspection-ready clinical trial operations.

Cisema supports overseas pharmaceutical and biotech companies with China clinical trial strategy, GCP compliance gap assessments, regulatory submissions, quality system alignment, and local implementation planning.

Contact Cisema to assess how the revised 2026 China GCP affects your clinical development program and to prepare your China trial operations before the new requirements take effect.

Further Information

• Explore Cisema’s pharmaceutical consulting services.

References

• Announcement of the NMPA, NHC, NATCM, and NDCPA on Issuing the Good Clinical Practice (GCP) for Drugs (No. 50 2026).

‍